Australia's most trusted
source of pharma news
Thursday, 19 February 2026
">
Posted 19 February 2026 AM
Mayne Pharma this week took legal action against Cosette and related entities over the aborted take-over of the Australian pharma last year.
The acquisition offer, and subsequent attempts by Cosette to get out of the deal, sent Mayne's share price on a roller-coaster ride in 2025. Since the Scheme Implementation Deed (SID) was terminated, Mayne's shares have fallen to a 10-year low.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.